抗帕金森病新药的研发进展  

Advancesof the Research and Development of New Anti-Parkinson's Disease Drugs

作　　者：阿丽塔[1] 刘晓婷[1] 王敏[1] 

机构地区：[1]中国医学科学院医学信息研究所,北京100005

出　　处：《中国药事》2012年第6期629-633,共5页Chinese Pharmaceutical Affairs

基　　金：国家科技图书文献中心基金项目"nstl面向艾滋病和病毒性肝炎等重大传染病防治科技重大专项的专业化信息服务"(编号2011XM53)

摘　　要：目的综述多巴胺能药物和其他新型治疗药物的研发状况,为国内的科研人员提供参考。方法分析了帕金森现有的主要治疗药物多巴胺能,包括左旋多巴胺、多巴胺受体激动剂、儿茶酚氧位甲基转移酶抑制剂、单胺氧化酶抑制剂等;以及新型的抗帕金森药物,包括α2-肾上腺素能受体拮抗剂、腺苷A2A受体拮抗剂、细胞治疗和基因治疗的基本原理、药物研发的进展情况。结果与结论帕金森病是一种渐进性的神经系统退行性疾病,在全球的发病率较高。新型治疗药物的研发成功有望缓解帕金森病人的痛苦,提高其生命质量,但新型药物的上市还有很长的过程。Objective In this article we summarized the current status of the research and development of the dopaminergie and other new drugs for treatment of Parkinson＇s disease to provide references for scientific research personnel of China. Methods We have analyzed the current therapeutic drugs including levodopa. Dopamine agonists, Catechol-O-methyltransferase, Monoamine oxidase inhibitor, etc and novel anti-PD drugs including a2-adrenergic receptor antagonist, Adenosine A2A Antagonists. We also discussed the basic princiles of the cell therapy and gene therapy and the progress of drug research and development. Results and Conclusion Parkinson＇s disease （PD） is a progressive neurological condition, having a high incidence. The success of the research and development of new anti-PD drugs will relieve the agony of the PD patients and enhance the life quality. However, there still is a long long way to go before they are available on the market.

关 键 词：帕金森 多巴胺能药物 细胞治疗 基因治疗 

分 类 号：R913[医药卫生—药学]